In 2020,
Supportive Regulatory Environment can Influence the Growth of the Market
Research and Development Opportunities Propel the Growth of the Market
Download Free Sample ReportGrowing Collaborations and Partnerships will Further Drive the Growth of the Market
Collaborative partnerships can support the optimization of manufacturing processes and scale-up efforts for cell and gene therapies. This includes knowledge sharing, process development, and technology transfer between organizations. By leveraging each other's expertise and resources, partners can address manufacturing challenges, improve scalability, and ensure efficient production of therapies. Collaborative manufacturing efforts enable the timely and cost-effective delivery of therapies to patients. Collaborative partnerships enable access to a diverse patient population for clinical trials and real-world evidence generation. By partnering with healthcare providers, patient advocacy groups, and patient registries, researchers, the companies can recruit participants, collect patient data, and engage with the patient community. Patient-centric collaborations foster awareness, understanding, and acceptance of cell and gene therapies, driving their growth and adoption.
Growing Demand for Innovative Treatments
As patients and their families become more informed about the potential benefits of cell and gene therapies, they are increasingly demanding access to these innovative treatments. The advocacy efforts of patient groups contribute to shaping policies, securing funding, and expanding access to cell and gene therapies in Canada.
Favorable investment climate
Clinical Trials Propels the Market Growth
Recent Development
- Kymriah (tisagenlecleucel)Kymriah, developed byNovartis, is a chimeric antigen receptor T-cell (CAR-T) therapy. It wasapproved by Health Canada in May 2019 for the treatment of pediatric and youngadult patients up to 25 years old with relapsed or refractory B-cell acutelymphoblastic leukemia (ALL). Kymriah is an innovative therapy that involvesgenetically modifying a patient's T-cells to recognize and attack cancer cells.
- Luxturna (voretigene neparvovec)Luxturna, developedby Spark Therapeutics (now part of Roche), is a gene therapy used for thetreatment of inherited retinal dystrophy caused by mutations in the RPE65 gene.It was approved by Health Canada in December 2019. Luxturna delivers afunctional copy of the RPE65 gene to the retinal cells, restoring vision inpatients with this rare genetic disorder.
- Zynteglo (autologous CD34+ cells encodingβA-T87Q-globin gene)Zynteglo, developed by bluebird bio. It is a gene therapyfor transfusion-dependent β-thalassemia. It was conditionally approved byHealth Canada in April 2021. Zynteglo involves genetically modifying apatient's own hematopoietic stem cells to produce functional hemoglobin. Thistherapy reduces or eliminates the need for blood transfusions in patients withtransfusion-dependent β-thalassemia.
Market Segmentation
Canada cell and gene therapy market can be segmented by type, indication, end user, and region. Based on type, Canada cell and gene therapy market can be divided into Cell Therapy v/s Gene Therapy. Based on indication, Canada cell and gene therapy market can be segmented into oncology diseases, cardiovascular diseases, orthopedic diseases, neurological diseases, and others. Based on end user, Canada cell and gene therapy market can be segmented into hospitals & clinics, academic & research institutions, and others. Regionally, Canada Cell and Gene therapy Market can be categorized into Quebec, Ontario, Alberta, British Columbia, Saskatchewan & Manitoba, and rest of Canada.
Market Players
Amgen Canada Inc, Kolon TissueGene Inc, Novartis Pharmaceuticals Canada Inc, Pfizer Canada Inc, Gilead Sciences Inc, Bristol-Myers Squibb Canada Inc, Merck & Co Inc are some of the leading players operating in the Canada Cell and Gene Therapy Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Type Indication End User Region |
| Regional scope | Quebec Region, Ontario Region, Alberta Region, British Columbia Region, Saskatchewan & Manitoba Region, Rest of Canada |
| Key companies profiled | Amgen Canada Inc, Kolon TissueGene Inc, Novartis Pharmaceuticals Canada Inc, Pfizer Canada Inc, Gilead Sciences Inc, Bristol-Myers Squibb Canada Inc, Merck & Co Inc |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
